Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
17 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Feb 24
S-8
Registration of securities for employees
16 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
19 Jul 23
8-K/A
Unregistered Sales of Equity Securities
10 Jul 23
DEFR14A
Revised proxy
7 Jun 23
DEFA14A
Additional proxy soliciting materials
7 Jun 23
DEF 14A
Definitive proxy
5 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
D
$6.01 mm in equity, sold $6.01 mm, 14 investors
14 Apr 23
8-K
Biostage Appoints Ron Packard to Board of Directors
10 Apr 23
8-K
Biostage Announces $6 Million Financing to Advance Clinical Trial
6 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Unregistered Sales of Equity Securities
14 Mar 23
8-K
Biostage Announces Chairman and CEO Transition
7 Mar 23
RW
Registration withdrawal request
1 Feb 23
8-K
Unregistered Sales of Equity Securities
26 Jan 23
8-K
Unregistered Sales of Equity Securities
12 Jan 23
8-K
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
28 Dec 22
8-K
Other Events
23 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Biostage Reports Corporate Highlights and Third Quarter Financial Results
14 Nov 22
S-1/A
IPO registration (amended)
27 Oct 22
8-K
Changes in Registrant's Certifying Accountant
12 Oct 22
8-K/A
Submission of Matters to a Vote of Security Holders
20 Sep 22
8-K
Biostage Announces Appointment of New Chief Financial Officer
10 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Biostage Reports Corporate Highlights and Second Quarter Financial Results
4 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
2 Aug 22
DEF 14A
Definitive proxy
6 Jul 22
PRE 14A
Preliminary proxy
22 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 22
S-1
IPO registration
21 Jun 22
8-K
Unregistered Sales of Equity Securities
13 Jun 22
D
$5.06M in equity / options / securities to be acquired, sold $5.06M, 25 investors
8 Jun 22
10-Q
2022 Q1
Quarterly report
16 May 22
Latest ownership filings
SC 13G/A
HARVARD BIOSCIENCE INC
13 Feb 24
4
Junli He
12 Jan 24
4
Junli He
3 Jan 24
4
Junli He
18 Dec 23
4
Junli He
11 Dec 23
4
Junli He
18 Sep 23
4
Junli He
5 Sep 23
4
Junli He
28 Aug 23
4
James E. Shmerling
23 Aug 23
4
Jing Chen
28 Jul 23
4
Herman Sanchez
28 Jul 23
4
Ting Li
28 Jul 23
4
James E. Shmerling
28 Jul 23
4
Ronald J Packard
28 Jul 23
4
DAVID GREEN
28 Jul 23
4/A
Junli He
10 Jul 23
4
Ronald J Packard
2 May 23
3
Ronald J Packard
2 May 23
4
Junli He
12 Apr 23
4
Change in insider ownership
10 Apr 23
4
DAVID GREEN
2 Mar 23
SC 13G/A
Zhang An
16 Feb 23
4
DAVID GREEN
27 Jan 23
4
Junli He
5 Jan 23
4
Change in insider ownership
9 Dec 22
4
Hong Yu
9 Dec 22
4
Jing Chen
9 Dec 22
3
JOSEPH LUIS DAMASIO JR
9 Aug 22
4
JOSEPH LUIS DAMASIO JR
9 Aug 22
4
James E. Shmerling
1 Jul 22
4
Herman Sanchez
1 Jul 22
4
Jing Chen
1 Jul 22
4
Ting Li
1 Jul 22
4
Junli He
1 Jul 22
SC 13G
HARVARD BIOSCIENCE INC
21 Jun 22
4
James E. Shmerling
23 May 22
4
DAVID GREEN
23 May 22
4
Junli He
20 May 22
4
Hong Yu
20 May 22
4
Change in insider ownership
19 May 22